Aumolertinib (trade name Ameile) is a pharmaceutical drug for the treatment of cancer. It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
In China, aumolertinib is approved for the treatment of patients with EGFR T790M mutation—positive non-small-cell lung cancer (NSCLC) who have progressed on or after other EGFR TKI therapy.
References
